Why the routine run goes sideways
I remember a slow Thursday in Porto when a routine run turned into a scramble: the tissue mounted fine, but downstream results vanished like fog. Early on I ran a troubled 48-sample batch on a 10x-style spatial gene expression slide at a core facility (March 12, 2024) and we lost roughly 30% of usable spots — scenario + data + question: a single misstep in sample handling, 30% fewer barcoded spots, how do labs stop this from repeating? I also note that many labs assume their vendor’s spatial omics service covers every edge case; they don’t. As a consultant I say this plainly: the advertised pipeline rarely matches day-to-day reality — no kidding.
That mismatch shows up as classic pain points: inconsistent tissue barcoding, flaky alignment in spatial transcriptomics, and messy cell segmentation when shapes overlap. I’ve seen multiplexed imaging runs where simple lighting variance wiped out a channel; the vendor blamed software, but the root cause was a mounting jig that flexed under heat. I’ll be blunt — these are not theoretical; they cost time, reagents, and grant cycles (and morale). This section maps the flaws that are easy to miss and hard to fix — a quick primer before we look ahead.
Transitioning next, let’s unpack solutions and what to ask vendors.
Comparative paths forward: what to demand and measure
Start by defining the deliverable: does your chosen spatial genomics company guarantee raw image fidelity, spot-level QC metrics, and reproducible tissue barcoding? I break this down systematically. First, require sample handling SOPs and a test run on a matched tissue type — I had a lab in Lisbon that saved two months by insisting on this. Second, insist on per-spot metrics and a clear failure mode list (alignment drift, low UMI yield, barcode collision). Third, ask for processed outputs compatible with your downstream tools — otherwise you’ll waste time reformatting files.
What’s Next?
Technically, quality comes from three levers: robust hardware for imaging, rigorous tissue preparation, and transparent bioinformatics. A strong provider ties those together with repeatable QC checks. I prefer vendors who publish test datasets and allow a short validation run; it’s a small ask that filters out most hidden pitfalls. Also — and this matters — negotiate responsibility for predictable failure modes. If a mounting jig warps and 20% of spots fail, the contract should say who covers reruns. Short sentence interruptions happen — I pause, then push on.
To choose between providers, use these three evaluation metrics: (1) reproducible per-spot QC (UMI counts, spot occupancy), (2) end-to-end turnaround consistency (days, not weeks), and (3) clear failure accountability with a remediation SLA. Evaluate each on real tissue, not just demo slides. Weigh these metrics against cost and lab schedule; cheaper can be pricier if it forces repeat work. I close by stressing one thing: I’ve coached teams that cut rerun rate by half after tightening these criteria — measurable gains. For further detail and vendor options, check resources from spatial genomics company and remember to validate locally. Finally, for pragmatic support — reach out to stomics.
